Kairos Pharma, Ltd.
KAPA
Positions held
Your positionsKAPA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $3.25M | Enterprise value | $622,112 | Trailing P/E | — | Forward P/E | -0.20 |
| PEG | — | Price / book | 0.70 | Beta | 1.44 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -114.0% | ROA | -66.9% | Debt / equity | — |
| Current ratio | 11.98 | Free cash flow | -$1.89M | Analyst recommendation | none | Mean target | $49.00 |
| 52w high | $9.24 | 52w low | $0.85 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$1.4M | -$1.7M | -$1.4M | -$1.4M | -$1.4M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$1.4M | -$1.7M | -$1.4M | -$1.4M | -$1.5M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$5.4M | -$2.6M | -$1.8M | -$1.1M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$5.6M | -$2.3M | -$1.7M | -$0.6M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-23 · Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
2026-09-09 · Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-21 · Kairos Pharma to Conduct 1-for-7 Reverse Stock Split
2026-08-21 · Kairos Pharma Announces 1-for-7 Reverse Stock Split
2026-08-04 · Bayer (XTRA:BAYN) Stock Still Looks Reasonable On New Prostate Cancer News
2026-07-22 · Bayer (XTRA:BAYN) Stock Gets Two New Research Deals In Cancer And Heart Health
2026-07-22 · Kairos Pharma Collaborates With Bayer to Assess Prostate Cancer Treatment Combination
2026-07-22 · Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
2026-07-15 · CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever
Price (daily)
Full chart · RSI · MACD · patterns